130 completed, 33 unknown, 19 recruiting, 19 terminated. 229 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 229 | Completed 130, Unknown 33, Recruiting 19, Terminated 19, Not yet recruiting 12, Active not recruiting 7, Withdrawn 5, Suspended 3, Enrolling by invitation 1 |
Follow Prostatic Diseases: new trials by email Literature Review of Prostatic Diseases trials Research Report on Prostatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy) - Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis) | Phase 4 | Not yet recruiting | University Hospital, Toulouse | 30 | 2027-02-01 | 2026-11-05 |
| Ceasing Alpha-blockers Early After Resection of the Prostate (The CLEAR Trial) Tamsulosin hydrochloride 0.2 mg, Placebo - Benign Prostatic Hyperplasia | Phase 4 | Not yet recruiting | Shanghai East Hospital | 400 | 2026-12-01 | 2026-09-29 |
| Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance Testosterone cypionate - Prostate Cancer, Hypogonadism, Male | Phase 4 | Recruiting | University of Miami | 35 | 2026-11-30 | 2026-11-02 |
| Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer. Darolutamide, Physician choice Androgen Deprivation (Hormone) Therapy - Prostate Cancer | Phase 4 | Not yet recruiting | University of Chicago | 80 | 2026-11-01 | 2026-01-08 |
| Perioperative Dutasteride for Hemorrhage Control in Bipolar TURP Under Anticoagulation. Dutasteride (0.5mg), Placebo - Benign Prostatic Hyperplasia, Postoperative Hemorrhage | Phase 4 | Not yet recruiting | Mohamed Mahmoud Dogha | 44 | 2026-10-21 | 2026-11-02 |
| Prospective Post Market Clinical Trial for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH. Zenflow Arm: Zenflow Spring System implant procedure, Medical Therapy Tamsulosin - Benign Prostatic Hyperplasia (BPH), Obstructive Lower Urinary Tract Symptoms (LUTS) | Phase 4 | Not yet recruiting | Zenflow, Inc. | 110 | 2026-09-01 | 2026-09-01 |
| Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients. Experimental - Elderly, Breast Cancer | Phase 4 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 794 | 2026-09-01 | 2026-09-03 |
| Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence fluciclovine (18F) - Prostate Cancer | Phase 4 | Recruiting | Blue Earth Diagnostics | 142 | 2026-08-31 | 2026-11-05 |
| Pupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients tamsulosin 0.4mg, Silodosin 8 mg - Benign Prostatic Hyperplasia, Silodosin | Phase 4 | Not yet recruiting | Mohsen Pourazizi | 40 | 2026-08-01 | 2026-08-03 |
| Iris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients tamsulosin 0.4mg, Silodosin 8 mg - Benign Prostatic Hyperplasia, Tamsulosin | Phase 4 | Not yet recruiting | Mohsen Pourazizi | 40 | 2026-08-01 | 2026-08-03 |
| Autonomic and Renal Contributions to Hypertension With ADT Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo - Androgen Deprivation Therapy, Prostate Cancer | Phase 4 | Recruiting | Virginia Commonwealth University | 60 | 2026-08-01 | 2026-11-02 |
| 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial Darolutamide combined with 177Lu-PSMA-617 - Prostate Cancer, Prostate Cancer Patients | Phase 4 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 20 | 2026-07-01 | 2026-07-01 |
| Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention Tamsulosin 0.4 mg, Tamsulosin 0.8 mg, Silodosin 8 mg - Acute Urinary Retention, Benign Prostatic Hyperplasia | Phase 4 | Recruiting | Beni-Suef University | 378 | 2026-06-08 | 2026-06-16 |
| Tamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia Tamsulosin, Tadalafil, Tadalafil Placebo - Acute Urinary Retention, Benign Prostatic Hyperplasia | Phase 4 | Recruiting | Beni-Suef University | 320 | 2026-06-08 | 2026-06-17 |
| The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder Intravesical Botox injection - Benign Prostatic Hyperplasia, Overactive Bladder | Phase 4 | Withdrawn | University Hospitals Cleveland Medical Center | 2026-06-01 | 2025-09-05 | |
| Tranexamic Acid for Bleeding Reduction During TURP Surgery Tranexamic Acid, Placebo (Normal Saline) - Benign Prostatic Hyperplasia, Transurethral Resection of the Prostate | Phase 4 | Recruiting | Hamza Najout | 80 | 2026-03-30 | 2026-10-09 |
| Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial Silodosin, Tamsulosin - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 4 | Not yet recruiting | Ain Shams University | 140 | 2026-03-22 | 2026-03-16 |
| Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers Morning administration of CDK4/6 inhibitor, Evening administration of CDK4/6 inhibitor, Morning administration of ARPI - Metastatic Breast Cancer, Metastatic Prostate Cancer | Phase 4 | Recruiting | Ottawa Hospital Research Institute | 50 | 2026-02-02 | 2026-07-17 |
| Comparison of Convective Water Vapor Ablation (Convective Water Vapor Energy, WAVE™) With the Rezum™ System Versus Holmium Laser Enucleation of the Prostate (HoLEP) Versus Bipolar Transurethral Resection of the Prostate (TUR-P) in Patients With Benign Prostatic Syndrome (BPS) - A Randomized Study Treatment BPH - BPH (Benign Prostatic Hyperplasia), HoLEP | Phase 4 | Not yet recruiting | Medical University of Graz | 198 | 2025-11-15 | 2025-11-19 |
| Standard Versus Double Alpha Blockers Treatment for Symptomatic Benign Prostatic Obstruction alpha blocker monotherapy Tamsulosin, alpha blockers Tamsulosin and Silodosin - BPH (Benign Prostatic Hyperplasia) | Phase 4 | Active not recruiting | Mansoura University | 140 | 2025-10-12 | 2026-11-05 |
Showing 20 of 229. Sign in to see all of them.
Prostatic Neoplasms (122) · Prostatic Hyperplasia (95) · Lower Urinary Tract Symptoms (16) · Prostatitis (13) · Breast Neoplasms (9) · Urinary Bladder, Overactive (9) · Neoplasms (8) · Pain (8) · Neoplasm Metastasis (5) · Erectile Dysfunction (4) · Kidney Diseases (4) · Kidney Neoplasms (4) · Colonic Neoplasms (3) · Hypogonadism (3)
Genital Diseases (229) · Genital Diseases, Male (228) · Male Urogenital Diseases (228) · Urogenital Diseases (228) · Neoplasms by Site (124) · Urogenital Neoplasms (124) · Genital Neoplasms, Male (122) · Neoplasms (117) · Pathological Conditions, Signs and Symptoms (52) · Signs and Symptoms (40) · Female Urogenital Diseases (29) · Female Urogenital Diseases and Pregnancy Complications (29) · Urologic Diseases (27) · Urological Manifestations (26)
Tamsulosin (28) · Dutasteride (15) · Zoledronic Acid (14) · silodosin (11) · Leuprolide (10) · alfuzosin (9) · bicalutamide (7) · Goserelin (6) · Tadalafil (6) · Triptorelin Pamoate (6) · enzalutamide (6) · Finasteride (5) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (5) · luprolide acetate gel depot (5) · Ciprofloxacin (4)
Novartis Pharmaceuticals (10) · GlaxoSmithKline (9) · Sanofi (8) · Mansoura University (7) · Astellas Pharma Inc (6) · Samsung Medical Center (5) · Boehringer Ingelheim (4) · Northwestern University (4) · Novartis (4) · University of Washington (4) · Beni-Suef University (3) · JW Pharmaceutical (3) · Radboud University Medical Center (3) · Seoul National University Hospital (3) · American Medical Systems (2)
United States (68) · South Korea (21) · Canada (18) · France (17) · Italy (17) · Egypt (15) · Spain (13) · Netherlands (12) · Germany (11) · China (8) · Turkey (Türkiye) (8) · United Kingdom (8) · Brazil (7) · Czechia (6) · Denmark (6)
Kyu-Sung Lee, Ph.D (4) · Richard E Berger, MD (3) · Ahmed M Elshal, MD (2) · Hassan Razvi, MD, FRCSC (2) · Heather Jacene, MD (2) · Matthew Babcock, PhD (2) · Paul F Siami, MD (2)
PMID 10411041, PMID 19524353, PMID 23334883, PMID 31937091, PMID 10524880, PMID 14713808, PMID 15249979, PMID 15310998, PMID 15592069, PMID 16465187, PMID 17724727, PMID 18708295, PMID 19143027, PMID 19394149, PMID 19732305, PMID 21251673, PMID 21575967, PMID 21738005, PMID 22010203, PMID 22405509, PMID 23186377, PMID 23452344, PMID 24354113, PMID 25038794, PMID 25261801, PMID 25613154, PMID 25627076, PMID 25988518, PMID 26544316, PMID 27286961, PMID 27324263, PMID 29044968, PMID 29394114, PMID 30028657, PMID 30224019, PMID 30300367, PMID 30352714, PMID 30787085, PMID 30939628, PMID 31148056, PMID 31329922, PMID 31643128, PMID 31797684, PMID 31961963, PMID 32444264, PMID 32558340, PMID 32632561, PMID 33245533, PMID 33258023, PMID 33299276
2023 (2), 2014 (1), 2015 (1), 2019 (1), 2025 (1), K01HL164978 (1), K12DK111028 (1), R01CA138627 (1), R01DK100924 (1)